ReNeuron’s balance sheet has been significantly strengthened following a £68.4m placing, enabling the group to progress its pipeline through to H1 2019 when two of its programmes (stroke and retinitis pigmentosa) should have reached filing stage. We have updated our forecasts in this note now the placing has been approved and updated our valuation to include retinitis pigmentosa as a Phase I/II trial is due to commence by the end of 2015. The group’s pipeline continues to progress with news flow ....
15 Sep 2015
Funded to H1 2019
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Funded to H1 2019
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
15 Sep 2015 -
Author:
N+1 Singer Team -
Pages:
8
ReNeuron’s balance sheet has been significantly strengthened following a £68.4m placing, enabling the group to progress its pipeline through to H1 2019 when two of its programmes (stroke and retinitis pigmentosa) should have reached filing stage. We have updated our forecasts in this note now the placing has been approved and updated our valuation to include retinitis pigmentosa as a Phase I/II trial is due to commence by the end of 2015. The group’s pipeline continues to progress with news flow ....